Gilead Sciences, Inc. (NASDAQ:GILD) will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.gilead.com
Earnings Expectation
Gilead Sciences, Inc. research-based biopharmaceutical firm, is reporting third quarter earnings results on Wednesday 28th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 1.95 per share from $ 6389.86 million in revenue. For the full year, analysts predict revenues of $ 24171.90 million, while looking forward to income of $ 6.98 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 23,000.00 million ~ $ 25,000.00 million, where as bottomline are predicted in a range of $ 6.25 ~ $ 7.65 per share
Click Here For More Historical Outlooks Of Gilead Sciences, Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The companys products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.
